HDAC9 and neoplasm: This strongly suggests that combining HDAC inhibition with checkpoint blockade could yield additional anti-tumor activity, thereby providing a strong rationale to consider exploring HDAC inhibition to overcome resistance to immunotherapy in clinical trials.